1. Cardiometabolic Risk: What Can the PPAR-Alpha Agonists Teach Us?

2. Panelists

3. Control of Gene Expression by the PPARs

6. Helsinki Heart Study: Effect of Gemfibrozil on Cardiac Events in Primary Prevention

7. VA-HIT: Effect of Gemfibrozil on Cardiac Events in Secondary Prevention

8. BIP: Effect of Bezafibrate on Cardiac Events in Secondary Prevention

10. ACCORD Lipid: Hazard Ratios for the Primary Outcome

11. FIELD: Effect of Fenofibrate on the Need for Laser Treatment for Diabetic Retinopathy

12. ACCORD Eye Sub-study: Progression of Diabetic Retinopathy

13. FIELD: Progression and Regression of Albuminuria

14. Impact of PPAR-a on HDL Particles

15. K-877 12-Week Phase 2 Trial: Study Design

16. K-877 12-Week Phase 2 Trial: Results

17. PROVE-IT: Residual CV Risk Remains After Moderate or Intensive Statin Therapy

18. The Concept of Dual PPAR-a/g Agonists

19. ALECARDIO: Aleglitazar in Patients With T2DM and ACS

20. Program Summary